2007年11月15日 · Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR.

2022年12月21日 · In this trial, we provide clinical evidence that KRAS G12C can be targeted in metastatic colorectal cancer, with activity observed for adagrasib as monotherapy and in combination with cetuximab...

2009年2月5日 · We studied the effect of adding the anti–epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal...

2023年5月1日 · Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor with the following FDA-approved indications: colorectal cancer, metastatic, KRAS wild-type (without mutation), and head and neck cancer (squamous cell).

Cetuximab is approved to be used alone or with other drugs to treat: Colorectal cancer that has spread to other parts of the body. It is used: In patients whose cancer has the EGFR protein and the wild-type KRAS gene. It is used: With FOLFIRI combination chemotherapy as …

2017年4月11日 · Several studies have shown that adding EGFR antibodies to chemotherapy in first-line treatment of metastatic colorectal cancer (mCRC) improves outcome (Bokemeyer et al, 2009; Van Cutsem et al,...

2024年1月18日 · Cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has revolutionized personalized treatment of metastatic colorectal cancer (mCRC) patients. This review highlights the mechanism of action, characteristics, and optimal indications for cetuximab in m …

2024年1月18日 · Cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has revolutionized personalized treatment of metastatic colorectal cancer (mCRC) patients. This review highlights the mechanism of action, characteristics, and optimal indications for cetuximab in mCRC.

2024年6月21日 · The US Food and Drug Administration has granted accelerated approval for the targeted therapy adagrasib (Krazati ®) in combination with the drug cetuximab (Erbitux ®) for people with advanced colorectal cancer caused by a gene mutation called KRAS -G12C. Adagrasib is the first KRAS-targeting drug to be approved for colorectal cancer.

Cetuximab is a chimeric monoclonal antibody highly selective for the epidermal growth factor receptor (EGFR), which is over-expressed by 25-80% of colorectal cancer tumours and associated with advanced disease.